CCN2 and diabetic kidney disease: In clinical studies, FG-3019, an anti-CTGF monoclonal antibody, reduced albuminuria in patients with diabetic kidney disease and slowed the rate of decline in forced vital capacity in patients with idiopathic pulmonary fibrosis with minimal adverse side effects21, 22.